Zim Laboratories Limited has informed the Exchange about Corrigendum to the Annual Report
ZIMLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Zim Laboratories has submitted a corrigendum to its FY25 Annual Report to fix inadvertent typographical errors in the Corporate Governance Report and the Independent Auditors Report. The revised annual report has been uploaded to the company's website. The 41st Annual General Meeting is scheduled for June 27, 2025. From the revised report, FY25 Total Operating Income stood at ₹3,790 Mn, up 3.2% YoY, with EBITDA at ₹495 Mn (margin 13.1%) and PAT at ₹122 Mn (margin 3.2%), lower than the ₹172 Mn reported in FY24 due to higher finance costs. Exports contributed 83% of revenue at ₹3,125 Mn, while the innovative products segment (NIP + OTF) grew strongly to ₹624 Mn, with NIP revenue up 82% to ₹437 Mn and OTF revenue up 42% to ₹186 Mn. The company received two EU marketing authorisations and invested ₹365 Mn in CapEx during the year.
The corrigendum is routine and relates only to typographical corrections, with no material changes to the financials or disclosures. Underlying FY25 performance shows modest revenue growth, expanding EBITDA margins, but a dip in PAT, while the strong growth in innovative products (NIP and OTF) signals a positive long-term growth trajectory for shareholders.